Analyzing the Most Promising Drugs That Will Lose Patent in the US & EU in 2022

Genito Urinary System and Sex Hormones

Market Heats Up as Managing Benign Prostatic Hy...

Benign prostatic hyperplasia, also called Benign prostatic hypertrophy or Benign prostatic obstruction, is a common condition in men as they get older. The prostate gland is a walnut-shaped gland p...

May 07, 2021

Merck, Eisai in renal cancer market; G1 Therapeutics on Cosela’s approval; Takeda’s Maribavir; Astellas/Seagen Padcev
Merck, Eisai in renal cancer market; G1 Therapeutics on Cosela’s approval; Takeda’s Maribavir; Astellas/Seagen Padcev

Merck's Keytruda-Eisai's Lenvima Combo Make the Cut in Renal Cancer Numerous immunotherapy-based combinations are already trying in the old game of gleek to stake up some share in previously untreated, metastatic kidney cancer; however, the market seems to expand as the new entrants continue to make their entry....

Find More
global-burden-of-sexually-transmitted-diseases-std
A Globally Rising Burden of Sexually Transmitted Diseases (STDs)

Caused by bacteria, viruses, and parasites, Sexually transmitted diseases (STDs) are a global health burden and it seems they are likely to maintain their status of being so in coming years also, primarily due to the lack of knowledge, and awareness. Further, diagnostics and screening, poverty, the stigma associate...

Find More
recent-pharma-happenings-for-nestle-gsk-astrazeneca
Nestle to acquire Aimmune Therapeutics; Vir Bio & GSK’s COVID-19 monoclonal antibody therapy; AstraZeneca’s Farxiga scores goal in Phase III CDK trial

Nestle acquires peanut allergy treatment with USD 2 Billion Aimmune buyout Nestle has announced a definitive agreement to extend its acquisition of Aimmune Therapeutics. Nestle will pay an additional amount of USD 2 Billion to buy the remaining shares of Aimmune. With the acquisition, Nestle will gain Aimmune's ...

Find More

More Views & Analysis

Interstitial-Cystitis-market-size-share-pipeline-analysis
Interstitial Cystitis: A big opportunities for emerging drugs

Interstitial Cystitis market comprises robust pipeline therapies in late and mid-stage development, which are expected to be launched shortly, such as KRP-116D (Kyorin Pharmaceutical), Certolizumab pegol/ Cimzia (UCB Pharma), LP-08 (Lipella Pharmaceuticals), GRT6010 (Grünenthal), ASP6294 (Astellas Pharma), and SI-...

Find More

Acute Kidney Injury Pipeline
Watch Out for the Most Promising Therapies in the Pipeline in Acute Kidney Injury Market

The Acute Kidney Injury Therapies in the pipeline anticipated to launch in the next decade shall spur the AKI Market growth forward. Acute Kidney Injury (AKI) is defined as a sudden advent of kidney failure or damage due to the accumulation of waste products in the bloodstream resulting in the improper fluid ou...

Find More

Acute Kidney Injury Market
Emerging Therapies that can significantly impact the Acute Kidney Injury Market

As per DelveInsight, Acute Kidney Injury Market Size in the 7 MM was observed to be USD 4,082.95 Million in 2017, which is expected to increase by 2030 significantly. Acute Kidney Injury (ARI), formerly known as Acute renal failure (ARF) is a sudden failure of kidneys or damages in the kidney resulting in an u...

Find More

Pharma News
Novome raises USD 33M, Buyout of Bioniz, Adagene raises USD 69M

A biotech company Novome Biotechnologies is developing novel live medicines for chronic diseases, has raised USD 33 Million in Series A financing. The financing was led by DCVC Bio with participation from seed investor 5AM Ventures, Alta Partners, Alexandria Venture Investments and Mayo Clinic. The company plan...

Find More

Autologous cell therapy market
Autologous cell therapy market: A new paradigm for kidney diseases

The past few decades have seen significant advancements in the medical sector. Technological intervention is one of them. Discovery of the remarkable property of Stem cells to be able to differentiate into different types of cell forms, replicate and express themselves as their parents is one of the milestone-disco...

Find More

Pharma news
GHO to advance healthcare in Europe; Truvian nets USD 27.1 Mn; Lilly plans its diabetes portfolio expansion

Global Healthcare Opportunities (GHO) Capital, a London-based healthcare investment firm, has recently netted USD 1.1 Billion to advance European healthcare. The company plans to use the proceeds to invest in healthcare companies. Closure of the second round capped at USD 1.1 Billion (Euro 975 Million) is the l...

Find More

Metachromatic Leukodystrophy (MLD) is a rare hereditary disease characterized by the accumulation of.....

Find More

A formal medical disorder affecting approximately 10 percent of the world population is trypanophobi.....

Find More

Soft Tissue Sarcoma (STS) tumors constitute 1% of all the malignancies. These are rare neoplasms tha.....

Find More

Major Depressive Disorder (MDD), also known as clinical depression, is a severe, debilitating and fr.....

Find More

Though appear rare, rare diseases are far from being rare. With over 7,000 rare disease affecting mi.....

Find More

Hospital-acquired bacterial pneumonia (HABP) is the most common type of health-care-associated infec.....

Find More